PE backer stumps up $12.3m to help Teewinot grow cannabinoid business

By Flora Southey contact

- Last updated on GMT

PE backer stumps up $12.3m to help Teewinot grow cannabinoid business

Related tags: Investment

Teewinot Life Sciences has closed a $12.3m (€11.2m) deal with investment manager Tuatara Capital.

The funds will be used to make cannabinoid pro-drugs with better bioavailability, increase large-scale manufacture, patent new therapies and move into clinical and pre-clinical trials,” ​Teewinot’s Executive Vice President, Richard Peet, told BioPharma-Reporter.

“The increased figure will also contribute to Teewinot’s expansion of business development opportunities,”​ Peet told us upon returning from meetings in Israel.

The last two years have seen an increase in Teewinot’s cannabinoid production capacity, and in the variety of cannabinoids it makes.

Teewinot claims its patent-protected biosynthetic cannabinoid manufacturing processes are more efficient than conventional chemical synthesis.

A Teewinot spokesperson said these methods “reduce cost and production time, increases purity of cannabinoids, and diversifies the number and types of molecules which can be made available to the research, product development, and commercial production verticals.”

Private equity cannabis backer

Florida-based Teewinot focuses on the production and delivery of cannabinoid-based therapies, and the biocatalytic production of cannabinoids.

New York-based Tuatara Capital is a private equity fund which invests in cannabis-related companies.

In 2015, Tuatara invested $7m (€6.4m) in Teewinot. The investment helped develop manufacturing processes responsible for the manufacture of kilogram quantities of pharmaceutically pure cannabinoids such as THCA, CBCA and THCVA.

Tuatara’s other cannabis related investments include a 2015 deal​ with American cannabis brand, Willie’s Reserve.

Teewinot currently produces 18 cannabinoids, including THCV, THC, CBD, CBDV and CBC.

Related news

Show more

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers